US6399754B1
(en)
|
1991-12-24 |
2002-06-04 |
Isis Pharmaceuticals, Inc. |
Sugar modified oligonucleotides
|
US6117847A
(en)
*
|
1992-03-16 |
2000-09-12 |
Isis Pharmaceuticals, Inc. |
Oligonucleotides for enhanced modulation of protein kinase C expression
|
US6346614B1
(en)
|
1992-07-23 |
2002-02-12 |
Hybridon, Inc. |
Hybrid oligonucleotide phosphorothioates
|
TW244371B
(ko)
*
|
1992-07-23 |
1995-04-01 |
Tri Clover Inc |
|
US5567604A
(en)
|
1993-04-23 |
1996-10-22 |
Aronex Pharmaceuticals, Inc. |
Anti-viral guanosine-rich oligonucleotides
|
US6288042B1
(en)
|
1993-04-23 |
2001-09-11 |
Aronex Pharmaceuticals, Inc. |
Anti-viral guanosine-rich tetrad forming oligonucleotides
|
US6323185B1
(en)
|
1993-04-23 |
2001-11-27 |
The United States Of America As Represented By The Department Of Health And Human Services |
Anti-viral guanosine-rich oligonucleotides and method of treating HIV
|
US6727230B1
(en)
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
US5981731A
(en)
*
|
1994-05-31 |
1999-11-09 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of B-raf gene expression
|
US6391636B1
(en)
|
1994-05-31 |
2002-05-21 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of raf gene expression
|
US20030026782A1
(en)
*
|
1995-02-07 |
2003-02-06 |
Arthur M. Krieg |
Immunomodulatory oligonucleotides
|
US6608035B1
(en)
*
|
1994-10-25 |
2003-08-19 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
US6645943B1
(en)
|
1994-10-25 |
2003-11-11 |
Hybridon, Inc. |
Method of down-regulating gene expression
|
US6040295A
(en)
*
|
1995-01-13 |
2000-03-21 |
Genemedicine, Inc. |
Formulated nucleic acid compositions and methods of administering the same for gene therapy
|
US6420549B1
(en)
|
1995-06-06 |
2002-07-16 |
Isis Pharmaceuticals, Inc. |
Oligonucleotide analogs having modified dimers
|
US20030119724A1
(en)
*
|
1995-11-22 |
2003-06-26 |
Ts`O Paul O.P. |
Ligands to enhance cellular uptake of biomolecules
|
US7812149B2
(en)
*
|
1996-06-06 |
2010-10-12 |
Isis Pharmaceuticals, Inc. |
2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
|
US20050053976A1
(en)
*
|
1996-06-06 |
2005-03-10 |
Baker Brenda F. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20040203024A1
(en)
*
|
1996-06-06 |
2004-10-14 |
Baker Brenda F. |
Modified oligonucleotides for use in RNA interference
|
US20040147022A1
(en)
*
|
1996-06-06 |
2004-07-29 |
Baker Brenda F. |
2'-methoxy substituted oligomeric compounds and compositions for use in gene modulations
|
US5898031A
(en)
*
|
1996-06-06 |
1999-04-27 |
Isis Pharmaceuticals, Inc. |
Oligoribonucleotides for cleaving RNA
|
US9096636B2
(en)
|
1996-06-06 |
2015-08-04 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
US20040171031A1
(en)
*
|
1996-06-06 |
2004-09-02 |
Baker Brenda F. |
Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
|
US20070275921A1
(en)
*
|
1996-06-06 |
2007-11-29 |
Isis Pharmaceuticals, Inc. |
Oligomeric Compounds That Facilitate Risc Loading
|
US20020165174A1
(en)
*
|
1997-01-31 |
2002-11-07 |
Gill Parkash S. |
Methods and compositions for antisense VEGF oligonucleotides
|
US6291667B1
(en)
|
1997-01-31 |
2001-09-18 |
Parkash S. Gill |
Method and composition for treatment of kaposi's sarcoma
|
EP0971944A4
(en)
*
|
1997-02-04 |
2005-01-26 |
Aronex Pharmaceuticals Inc |
ANTIVIRAL OLIGONUCLEOTIDES RICH IN GUANOSINE FORMING TETRADES
|
AU6553398A
(en)
*
|
1997-03-12 |
1998-09-29 |
Hybridon, Inc. |
Down-regulation of gene expression by colorectal administration of synthetic oligonucleotides
|
EP0979309A4
(en)
*
|
1997-04-30 |
2000-10-18 |
Isis Pharmaceuticals Inc |
OLIGONUCLEOTIDES WITH IMPROVED BIOAVAILABILITY
|
WO1999001579A1
(en)
*
|
1997-07-01 |
1999-01-14 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for the delivery of oligonucleotides via the alimentary canal
|
JP2001514884A
(ja)
*
|
1997-08-19 |
2001-09-18 |
ハイブリドン・インク |
新規なhiv特異的合成オリゴヌクレオチド及びその使用方法
|
US6306831B1
(en)
|
1997-09-12 |
2001-10-23 |
Qik Technologies, Inc. |
Transplacental delivery of oligonucleotides
|
US6127535A
(en)
|
1997-11-05 |
2000-10-03 |
Ribozyme Pharmaceuticals, Inc. |
Nucleoside triphosphates and their incorporation into oligonucleotides
|
US6617438B1
(en)
|
1997-11-05 |
2003-09-09 |
Sirna Therapeutics, Inc. |
Oligoribonucleotides with enzymatic activity
|
US20040171564A1
(en)
*
|
1997-11-20 |
2004-09-02 |
Honkanen Richard E. |
Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression
|
US5948902A
(en)
*
|
1997-11-20 |
1999-09-07 |
South Alabama Medical Science Foundation |
Antisense oligonucleotides to human serine/threonine protein phosphatase genes
|
US20040063618A1
(en)
*
|
2002-09-30 |
2004-04-01 |
Muthiah Manoharan |
Peptide nucleic acids having improved uptake and tissue distribution
|
US20040186071A1
(en)
*
|
1998-04-13 |
2004-09-23 |
Bennett C. Frank |
Antisense modulation of CD40 expression
|
US6197584B1
(en)
*
|
1998-05-01 |
2001-03-06 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of CD40 expression
|
WO1999060012A1
(en)
*
|
1998-05-21 |
1999-11-25 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for non-parenteral delivery of oligonucleotides
|
US6077709A
(en)
|
1998-09-29 |
2000-06-20 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Survivin expression
|
US6235891B1
(en)
|
1999-03-31 |
2001-05-22 |
South Alabama Medical Science Foundation |
Glucocorticoid receptor agonist and decreased PP5
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
US6977245B2
(en)
|
1999-04-12 |
2005-12-20 |
The United States Of America As Represented By The Department Of Health And Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
DE60017259T2
(de)
*
|
1999-08-13 |
2005-12-08 |
Hybridon, Inc., Cambridge |
Modulation der CPG-Oligonukleotid-vermittelten Immunstimulation durch Positionsbedingte Modifikation von Nukleosiden
|
US20010011126A1
(en)
*
|
1999-09-10 |
2001-08-02 |
Bock Elisabeth Marianne |
Neurogenic compositions and methods
|
US6617442B1
(en)
*
|
1999-09-30 |
2003-09-09 |
Isis Pharmaceuticals, Inc. |
Human Rnase H1 and oligonucleotide compositions thereof
|
ATE378348T1
(de)
*
|
2000-01-14 |
2007-11-15 |
Us Health |
Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US20030176385A1
(en)
*
|
2000-02-15 |
2003-09-18 |
Jingfang Ju |
Antisense modulation of protein expression
|
US6680172B1
(en)
|
2000-05-16 |
2004-01-20 |
Regents Of The University Of Michigan |
Treatments and markers for cancers of the central nervous system
|
KR100607612B1
(ko)
|
2001-06-20 |
2006-08-02 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
US7803915B2
(en)
*
|
2001-06-20 |
2010-09-28 |
Genentech, Inc. |
Antibody compositions for the diagnosis and treatment of tumor
|
US20050107595A1
(en)
*
|
2001-06-20 |
2005-05-19 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
EP2221376B1
(en)
|
2001-06-21 |
2012-11-21 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of superoxide dismutase 1, soluble expression
|
US7425545B2
(en)
|
2001-07-25 |
2008-09-16 |
Isis Pharmaceuticals, Inc. |
Modulation of C-reactive protein expression
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US7666674B2
(en)
|
2001-07-27 |
2010-02-23 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
WO2003020884A2
(en)
*
|
2001-08-14 |
2003-03-13 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services |
Method for rapid generation of mature dendritic cells
|
US20030096781A1
(en)
*
|
2001-08-31 |
2003-05-22 |
University Of Southern California |
IL-8 is an autocrine growth factor and a surrogate marker for Kaposi's sarcoma
|
EP1487877B1
(en)
|
2001-09-18 |
2010-10-27 |
Genentech, Inc. |
Compositions and methods for the diagnosis of tumors
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
NZ577565A
(en)
|
2001-10-09 |
2010-10-29 |
Isis Pharmaceuticals Inc |
Antisense modulation of insulin-like growth factor binding protein 5 expressions
|
US20030165859A1
(en)
*
|
2001-10-23 |
2003-09-04 |
Invitrogen Corporation |
Primers and methods for the detection and discrimination of nucleic acids
|
EP1575976A4
(en)
|
2001-11-02 |
2006-08-23 |
Insert Therapeutics Inc |
METHODS AND COMPOSITIONS FOR THE THERAPEUTIC USE OF RNA INTERFERENCE
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
US8466116B2
(en)
|
2001-12-20 |
2013-06-18 |
The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Use of CpG oligodeoxynucleotides to induce epithelial cell growth
|
WO2003054161A2
(en)
*
|
2001-12-20 |
2003-07-03 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
|
KR20070087247A
(ko)
|
2002-01-02 |
2007-08-27 |
제넨테크, 인크. |
종양의 진단 및 치료 방법 및 이를 위한 조성물
|
US20030191075A1
(en)
*
|
2002-02-22 |
2003-10-09 |
Cook Phillip Dan |
Method of using modified oligonucleotides for hepatic delivery
|
US20030180712A1
(en)
|
2002-03-20 |
2003-09-25 |
Biostratum Ab |
Inhibition of the beta3 subunit of L-type Ca2+ channels
|
EP1571968A4
(en)
|
2002-04-16 |
2007-10-17 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF TUMORS
|
US7199107B2
(en)
|
2002-05-23 |
2007-04-03 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of kinesin-like 1 expression
|
WO2003101386A2
(en)
|
2002-05-30 |
2003-12-11 |
Memorial Sloan-Kettering Cancer Center |
Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis
|
US7301017B2
(en)
*
|
2002-05-30 |
2007-11-27 |
Kolesnick Richard N |
Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
|
US20050196382A1
(en)
*
|
2002-09-13 |
2005-09-08 |
Replicor, Inc. |
Antiviral oligonucleotides targeting viral families
|
JP2005538186A
(ja)
*
|
2002-09-13 |
2005-12-15 |
レプリコール インコーポレーティッド |
非配列相補性の抗ウイルス性オリゴヌクレオチド
|
US8263091B2
(en)
*
|
2002-09-18 |
2012-09-11 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
|
WO2004031350A2
(en)
|
2002-09-26 |
2004-04-15 |
Amgen, Inc. |
Modulation of forkhead box o1a expression
|
EP1560597A4
(en)
*
|
2002-10-29 |
2007-06-27 |
Pharmacia Corp |
DIFFERENTIALLY EXPRESSED GENES INVOLVED IN CANCER, POLYPEPTIDES CODED THEREWITH, AND METHODS OF USING GENES
|
WO2004044138A2
(en)
|
2002-11-05 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Chimeric oligomeric compounds and their use in gene modulation
|
EP2957568B1
(en)
*
|
2002-11-05 |
2016-12-21 |
Ionis Pharmaceuticals, Inc. |
Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
|
DK1569695T3
(da)
|
2002-11-13 |
2013-08-05 |
Genzyme Corp |
Antisense-modulering af apolipoprotein-b-ekspression
|
WO2004044181A2
(en)
|
2002-11-13 |
2004-05-27 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein b expression
|
US7144999B2
(en)
|
2002-11-23 |
2006-12-05 |
Isis Pharmaceuticals, Inc. |
Modulation of hypoxia-inducible factor 1 alpha expression
|
US7371840B2
(en)
|
2003-01-08 |
2008-05-13 |
The University Of Southern California |
Isolation and characterization of ECA1, a gene overexpressed in endometrioid carcinomas of ovary and endometrium
|
US7468356B2
(en)
|
2003-02-11 |
2008-12-23 |
Antisense Therapeutics Ltd. |
Modulation of insulin like growth factor I receptor expression
|
US7803781B2
(en)
|
2003-02-28 |
2010-09-28 |
Isis Pharmaceuticals, Inc. |
Modulation of growth hormone receptor expression and insulin-like growth factor expression
|
US20040185559A1
(en)
|
2003-03-21 |
2004-09-23 |
Isis Pharmaceuticals Inc. |
Modulation of diacylglycerol acyltransferase 1 expression
|
US20040198640A1
(en)
*
|
2003-04-02 |
2004-10-07 |
Dharmacon, Inc. |
Stabilized polynucleotides for use in RNA interference
|
US7598227B2
(en)
|
2003-04-16 |
2009-10-06 |
Isis Pharmaceuticals Inc. |
Modulation of apolipoprotein C-III expression
|
CA2522184A1
(en)
*
|
2003-04-17 |
2004-11-04 |
The Trustees Of Columbia University In The City Of New York |
Desmoglein 4 is a novel gene involved in hair growth
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
AU2004253455B2
(en)
|
2003-06-03 |
2011-03-03 |
Eli Lilly And Company |
Modulation of survivin expression
|
WO2005044976A2
(en)
*
|
2003-06-20 |
2005-05-19 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds for use in gene modulation
|
EP2530157B1
(en)
|
2003-07-31 |
2016-09-28 |
Regulus Therapeutics Inc. |
Oligomeric compounds and compositions for use in modulation of miRNAs
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
US20070123480A1
(en)
*
|
2003-09-11 |
2007-05-31 |
Replicor Inc. |
Oligonucleotides targeting prion diseases
|
CN100558893C
(zh)
|
2003-09-18 |
2009-11-11 |
Isis药物公司 |
eIF4E表达的调节
|
EP1678194B1
(en)
|
2003-10-10 |
2013-06-26 |
Alchemia Oncology Pty Limited |
The modulation of hyaluronan synthesis and degradation in the treatment of disease
|
US20050191653A1
(en)
|
2003-11-03 |
2005-09-01 |
Freier Susan M. |
Modulation of SGLT2 expression
|
DK2295073T3
(da)
|
2003-11-17 |
2014-07-28 |
Genentech Inc |
Antistof mod cd22 til behandling af tumor af hæmatopoietisk oprindelse
|
JP2007520222A
(ja)
|
2004-01-20 |
2007-07-26 |
アイシス ファーマシューティカルズ インコーポレイテッド |
グルココルチコイドレセプター発現の調節
|
US7468431B2
(en)
*
|
2004-01-22 |
2008-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of eIF4E-BP2 expression
|
US20090280567A1
(en)
*
|
2004-02-06 |
2009-11-12 |
Dharmacon, Inc. |
Stabilized sirnas as transfection controls and silencing reagents
|
US8569474B2
(en)
*
|
2004-03-09 |
2013-10-29 |
Isis Pharmaceuticals, Inc. |
Double stranded constructs comprising one or more short strands hybridized to a longer strand
|
US8790919B2
(en)
|
2004-03-15 |
2014-07-29 |
Isis Pharmaceuticals, Inc. |
Compositions and methods for optimizing cleavage of RNA by RNase H
|
WO2005097207A2
(en)
*
|
2004-03-26 |
2005-10-20 |
Curis, Inc. |
Rna interference modulators of hedgehog signaling and uses thereof
|
KR101147147B1
(ko)
*
|
2004-04-01 |
2012-05-25 |
머크 샤프 앤드 돔 코포레이션 |
Rna 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드
|
US20050244869A1
(en)
*
|
2004-04-05 |
2005-11-03 |
Brown-Driver Vickie L |
Modulation of transthyretin expression
|
AU2004320622B2
(en)
*
|
2004-06-03 |
2012-06-14 |
Isis Pharmaceuticals, Inc. |
Chimeric gapped oligomeric compositions
|
CA2569419A1
(en)
*
|
2004-06-03 |
2005-12-22 |
Isis Pharmaceuticals, Inc. |
Double strand compositions comprising differentially modified strands for use in gene modulation
|
US8394947B2
(en)
*
|
2004-06-03 |
2013-03-12 |
Isis Pharmaceuticals, Inc. |
Positionally modified siRNA constructs
|
US7884086B2
(en)
*
|
2004-09-08 |
2011-02-08 |
Isis Pharmaceuticals, Inc. |
Conjugates for use in hepatocyte free uptake assays
|
US9315862B2
(en)
*
|
2004-10-05 |
2016-04-19 |
California Institute Of Technology |
Aptamer regulated nucleic acids and uses thereof
|
US20060105348A1
(en)
*
|
2004-11-15 |
2006-05-18 |
Lee Jun E |
Compositions and methods for the detection and discrimination of nucleic acids
|
US20060275792A1
(en)
*
|
2004-11-15 |
2006-12-07 |
Lee Jun E |
Enhancement of nucleic acid amplification using double-stranded DNA binding proteins
|
US20060166234A1
(en)
*
|
2004-11-22 |
2006-07-27 |
Barbara Robertson |
Apparatus and system having dry control gene silencing compositions
|
US7923207B2
(en)
|
2004-11-22 |
2011-04-12 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing pools
|
US7935811B2
(en)
*
|
2004-11-22 |
2011-05-03 |
Dharmacon, Inc. |
Apparatus and system having dry gene silencing compositions
|
EP1855694B1
(en)
|
2005-02-09 |
2020-12-02 |
Sarepta Therapeutics, Inc. |
Antisense composition for treating muscle atrophy
|
KR20070110077A
(ko)
|
2005-03-10 |
2007-11-15 |
제넨테크, 인크. |
혈관 완전성을 조정하기 위한 방법 및 조성물
|
US20060223777A1
(en)
*
|
2005-03-29 |
2006-10-05 |
Dharmacon, Inc. |
Highly functional short hairpin RNA
|
WO2006105361A2
(en)
|
2005-03-31 |
2006-10-05 |
Calando Pharmaceuticals, Inc. |
Inhibitors of ribonucleotide reductase subunit 2 and uses thereof
|
US8097597B2
(en)
|
2005-05-05 |
2012-01-17 |
Antisense Pharma Gmbh |
Use of low doses of oligonucleotides antisense to TGF-β genes in the treatment of brain tumors
|
EP1966377A2
(en)
|
2005-11-21 |
2008-09-10 |
Isis Pharmaceuticals, Inc. |
Modulation of eif4e-bp2 expression
|
DK2161038T3
(da)
|
2006-01-26 |
2014-03-03 |
Isis Pharmaceuticals Inc |
Sammensætninger og deres anvendelser rettet mod Huntington
|
EP2614839A3
(en)
|
2006-04-05 |
2015-01-28 |
Genentech, Inc. |
Method for using BOC/CDO to modulate hedgehog signaling
|
JP2009535383A
(ja)
*
|
2006-05-03 |
2009-10-01 |
バルティック テクロノジー デヴェロプメント,リミテッド |
強く結合した塩基で修飾されたオリゴヌクレオチドと人工ヌクレアーゼを組み合わせたアンチセンス作用物質
|
US20090209625A1
(en)
*
|
2006-05-23 |
2009-08-20 |
Sanjay Bhanot |
Modulation of chrebp expression
|
US8198253B2
(en)
|
2006-07-19 |
2012-06-12 |
Isis Pharmaceuticals, Inc. |
Compositions and their uses directed to HBXIP
|
EP3342415B1
(en)
|
2006-08-08 |
2022-01-26 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Structure and use of 5' phosphate oligonucleotides
|
GB0617429D0
(en)
|
2006-09-05 |
2006-10-18 |
Electrophoretics Ltd |
Markers of renal transplant rejection and renal damage
|
AU2007299705B2
(en)
*
|
2006-09-22 |
2012-09-06 |
Dharmacon, Inc. |
Duplex oligonucleotide complexes and methods for gene silencing by RNA interference
|
US8158595B2
(en)
*
|
2006-11-09 |
2012-04-17 |
California Institute Of Technology |
Modular aptamer-regulated ribozymes
|
WO2008086807A2
(en)
|
2007-01-19 |
2008-07-24 |
Exiqon A/S |
Mediated cellular delivery of lna oligonucleotides
|
EP2114981B1
(en)
|
2007-01-29 |
2013-05-08 |
Isis Pharmaceuticals, Inc. |
Compounds and methods for modulating protein expression
|
CA2676790A1
(en)
|
2007-02-22 |
2008-08-28 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
US20090082217A1
(en)
*
|
2007-07-16 |
2009-03-26 |
California Institute Of Technology |
Selection of nucleic acid-based sensor domains within nucleic acid switch platform
|
US8367815B2
(en)
*
|
2007-08-28 |
2013-02-05 |
California Institute Of Technology |
Modular polynucleotides for ligand-controlled regulatory systems
|
US20120165387A1
(en)
|
2007-08-28 |
2012-06-28 |
Smolke Christina D |
General composition framework for ligand-controlled RNA regulatory systems
|
US8865667B2
(en)
*
|
2007-09-12 |
2014-10-21 |
California Institute Of Technology |
Higher-order cellular information processing devices
|
JP2010539978A
(ja)
|
2007-10-02 |
2010-12-24 |
アムジェン インコーポレイテッド |
マイクロ−rnaおよびその前駆体にハイブリダイズしうる核酸を用いるエリスロポエチンの増加
|
WO2009060124A2
(en)
*
|
2007-11-05 |
2009-05-14 |
Baltic Technology Development, Ltd. |
Use of oligonucleotides with modified bases in hybridization of nucleic acids
|
US8916531B2
(en)
*
|
2007-11-20 |
2014-12-23 |
Isis Pharmaceuticals, Inc. |
Modulation of CD40 expression
|
US9029524B2
(en)
*
|
2007-12-10 |
2015-05-12 |
California Institute Of Technology |
Signal activated RNA interference
|
US20100119528A1
(en)
*
|
2008-01-17 |
2010-05-13 |
Gobinda Sarkar |
Transport of Biologically Active Molecules into a Cell, Mitochondrion, or Nucleus
|
WO2009102427A2
(en)
*
|
2008-02-11 |
2009-08-20 |
Rxi Pharmaceuticals Corp. |
Modified rnai polynucleotides and uses thereof
|
US8188060B2
(en)
|
2008-02-11 |
2012-05-29 |
Dharmacon, Inc. |
Duplex oligonucleotides with enhanced functionality in gene regulation
|
KR20100127880A
(ko)
|
2008-04-04 |
2010-12-06 |
카란도 파마슈티칼즈, 인코포레이티드 |
Epas1 억제제의 조성물 및 용도
|
EP2297323A1
(en)
|
2008-05-21 |
2011-03-23 |
Hartmann, Gunther |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
US8815818B2
(en)
|
2008-07-18 |
2014-08-26 |
Rxi Pharmaceuticals Corporation |
Phagocytic cell delivery of RNAI
|
EP2323667A4
(en)
*
|
2008-08-07 |
2012-07-25 |
Isis Pharmaceuticals Inc |
MODULATION OF TRANSTHYRETIN EXPRESSION BY TREATMENT OF CNS DISEASES
|
CN107083386A
(zh)
|
2008-08-25 |
2017-08-22 |
埃克斯雷德制药有限公司 |
阻止***生长因子的反义核苷酸及其用途
|
EP3336188B1
(en)
|
2008-09-22 |
2020-05-06 |
Phio Pharmaceuticals Corp. |
Reduced size self-delivering rnai compounds
|
WO2010059226A2
(en)
|
2008-11-19 |
2010-05-27 |
Rxi Pharmaceuticals Corporation |
Inhibition of map4k4 through rnai
|
CN108042560A
(zh)
|
2008-12-04 |
2018-05-18 |
库尔纳公司 |
通过抑制针对沉默调节蛋白1的天然反义转录物来治疗沉默调节蛋白1相关的疾病
|
JP6091752B2
(ja)
|
2008-12-04 |
2017-03-08 |
クルナ・インコーポレーテッド |
Epoに対する天然アンチセンス転写物の抑制によるエリスロポエチン(epo)関連疾患の治療
|
WO2010065787A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
|
US9493774B2
(en)
|
2009-01-05 |
2016-11-15 |
Rxi Pharmaceuticals Corporation |
Inhibition of PCSK9 through RNAi
|
WO2010090762A1
(en)
|
2009-02-04 |
2010-08-12 |
Rxi Pharmaceuticals Corporation |
Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
|
CN102439149B
(zh)
|
2009-02-12 |
2018-01-02 |
库尔纳公司 |
通过抑制针对胶质细胞衍生神经营养因子(gdnf)的天然反义转录物来治疗gdnf相关的疾病
|
CN102387817B
(zh)
|
2009-02-12 |
2018-01-30 |
库尔纳公司 |
通过抑制针对脑衍生神经营养因子(bdnf)的天然反义转录物来治疗bdnf相关的疾病
|
US8329882B2
(en)
|
2009-02-18 |
2012-12-11 |
California Institute Of Technology |
Genetic control of mammalian cells with synthetic RNA regulatory systems
|
JP6250263B2
(ja)
|
2009-03-04 |
2017-12-20 |
クルナ・インコーポレーテッド |
サーチュイン1(sirt1)に対する天然アンチセンス転写物の抑制によるsirt1関連疾患の治療
|
EP2408919B1
(en)
|
2009-03-16 |
2017-10-18 |
CuRNA, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2
|
JP5904935B2
(ja)
|
2009-03-17 |
2016-04-20 |
クルナ・インコーポレーテッド |
デルタ様1ホモログ(dlk1)に対する天然アンチセンス転写物の抑制によるdlk1関連疾患の治療
|
US9145555B2
(en)
|
2009-04-02 |
2015-09-29 |
California Institute Of Technology |
Integrated—ligand-responsive microRNAs
|
EP3248618A1
(en)
|
2009-04-22 |
2017-11-29 |
Massachusetts Institute Of Technology |
Innate immune suppression enables repeated delivery of long rna molecules
|
WO2010127195A2
(en)
|
2009-05-01 |
2010-11-04 |
Curna, Inc. |
Antisense oligonucleotides of hemoglobins
|
CN103223177B
(zh)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
WO2010129746A2
(en)
|
2009-05-06 |
2010-11-11 |
Curna, Inc. |
Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp
|
CA2762369C
(en)
|
2009-05-18 |
2021-12-28 |
Joseph Collard |
Treatment of reprogramming factor related diseases by inhibition of natural antisense transcript to a reprogramming factor
|
JP2012527248A
(ja)
|
2009-05-22 |
2012-11-08 |
クルナ・インコーポレーテッド |
転写因子e3(tfe3)に対する天然アンチセンス転写物の阻害によるtfe3およびインスリン受容体基質2(irs2)関連疾患の処置
|
US8791085B2
(en)
|
2009-05-28 |
2014-07-29 |
Curna, Inc. |
Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene
|
JP5944311B2
(ja)
|
2009-06-16 |
2016-07-05 |
クルナ・インコーポレーテッド |
コラーゲン遺伝子に対する天然アンチセンス転写物の抑制によるコラーゲン遺伝子関連疾患の治療
|
WO2010148065A2
(en)
|
2009-06-16 |
2010-12-23 |
Curna, Inc. |
Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
|
EP2446036B1
(en)
|
2009-06-24 |
2017-03-01 |
CuRNA, Inc. |
Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
|
EP2446037B1
(en)
|
2009-06-26 |
2016-04-20 |
CuRNA, Inc. |
Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
|
PL2453923T3
(pl)
|
2009-07-14 |
2016-06-30 |
Mayo Found Medical Education & Res |
Niekowalencyjne dostarczanie aktywnych czynników przez barierę krew-mózg przy udziale peptydów
|
WO2011017516A2
(en)
|
2009-08-05 |
2011-02-10 |
Curna, Inc. |
Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins)
|
EP2470657B1
(en)
|
2009-08-25 |
2019-10-23 |
CuRNA, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
DK2473522T3
(en)
|
2009-09-02 |
2016-11-28 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
WO2011046983A2
(en)
|
2009-10-12 |
2011-04-21 |
Smith Holdings, Llc |
Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
|
CN102711826B
(zh)
|
2009-10-22 |
2017-03-29 |
霍夫曼-拉罗奇有限公司 |
用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
|
US20120244169A1
(en)
|
2009-11-06 |
2012-09-27 |
Fibrogen, Inc. |
Treatment for Radiation-Induced Disorders
|
WO2011066503A2
(en)
|
2009-11-30 |
2011-06-03 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
BR112012014022A2
(pt)
|
2009-12-11 |
2017-04-04 |
Genecode As |
composto, composição, dispositivo médico e método ex vivo para modulação do crescimento de um neurônico
|
US9173895B2
(en)
|
2009-12-16 |
2015-11-03 |
Curna, Inc. |
Treatment of membrane bound transcription factor peptidase, site 1 (MBTPS1) related diseases by inhibition of natural antisense transcript to MBTPS1
|
ES2661387T3
(es)
|
2009-12-23 |
2018-03-28 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor de crecimiento de hepatocitos (hgf) mediante inhibición del transcrito antisentido natural a hgf
|
EP2515947B1
(en)
|
2009-12-23 |
2021-10-06 |
CuRNA, Inc. |
Treatment of uncoupling protein 2 (ucp2) related diseases by inhibition of natural antisense transcript to ucp2
|
WO2011090741A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
WO2011090740A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
ES2664605T3
(es)
|
2010-01-04 |
2018-04-20 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el factor 8 regulador del interferón (irf8) mediante inhibición del transcrito antisentido natural al gen irf8
|
US8912157B2
(en)
|
2010-01-06 |
2014-12-16 |
Curna, Inc. |
Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene
|
US9200277B2
(en)
|
2010-01-11 |
2015-12-01 |
Curna, Inc. |
Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
|
WO2011090971A2
(en)
|
2010-01-19 |
2011-07-28 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for male reproductive disorders
|
JP5981850B2
(ja)
|
2010-01-25 |
2016-08-31 |
カッパーアールエヌエー,インコーポレイテッド |
RNaseH1に対する天然アンチセンス転写物の阻害によるRNaseH1関連疾患の治療
|
CN102844435B
(zh)
|
2010-02-22 |
2017-05-10 |
库尔纳公司 |
通过抑制吡咯啉‑5‑羧酸还原酶1(pycr1)的天然反义转录物而治疗pycr1相关疾病
|
KR20130004579A
(ko)
|
2010-02-23 |
2013-01-11 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 조성물 및 방법
|
AU2011219029B2
(en)
|
2010-02-26 |
2017-02-02 |
Columbia University |
Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets
|
EP2550001B1
(en)
|
2010-03-24 |
2019-05-22 |
Phio Pharmaceuticals Corp. |
Rna interference in ocular indications
|
WO2011119852A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Pharmaceuticals Corporation |
Reduced size self-delivering rnai compounds
|
WO2011119887A1
(en)
|
2010-03-24 |
2011-09-29 |
Rxi Pharmaceuticals Corporation |
Rna interference in dermal and fibrotic indications
|
CN102858979B
(zh)
|
2010-04-09 |
2018-01-26 |
库尔纳公司 |
通过抑制成纤维细胞生长因子21(fgf21)的天然反义转录物而治疗fgf21相关疾病
|
CN103038345B
(zh)
|
2010-04-29 |
2017-07-21 |
Ionis制药公司 |
转甲状腺素蛋白表达的调节
|
MX342239B
(es)
|
2010-05-03 |
2016-09-21 |
Genentech Inc * |
Composiciones y metodos para el diagnostico y tratamiento de tumores.
|
KR101915115B1
(ko)
|
2010-05-03 |
2018-11-05 |
큐알엔에이, 인크. |
시르투인 (sirt)에 대한 자연 안티센스 전사체의 저해에 의한 시르투인 (sirt) 관련된 질환의 치료
|
CN109593814A
(zh)
|
2010-05-12 |
2019-04-09 |
哥伦比亚大学纽约管理委员会 |
筛选分析、鉴别药剂的方法及药物组合物
|
TWI586356B
(zh)
|
2010-05-14 |
2017-06-11 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
CN107412251A
(zh)
|
2010-05-26 |
2017-12-01 |
库尔纳公司 |
通过抑制无调同源物1(atoh1)的天然反义转录物而治疗atoh1相关疾病
|
JP5998131B2
(ja)
|
2010-07-14 |
2016-09-28 |
カッパーアールエヌエー,インコーポレイテッド |
Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療
|
DK2625197T3
(en)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
US8993533B2
(en)
|
2010-10-06 |
2015-03-31 |
Curna, Inc. |
Treatment of sialidase 4 (NEU4) related diseases by inhibition of natural antisense transcript to NEU4
|
US9222088B2
(en)
|
2010-10-22 |
2015-12-29 |
Curna, Inc. |
Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
|
CN103201387B
(zh)
|
2010-10-27 |
2018-02-02 |
库尔纳公司 |
通过抑制干扰素相关发育调节因子1(ifrd1)的天然反义转录物而治疗ifrd1相关疾病
|
WO2012061811A2
(en)
|
2010-11-05 |
2012-05-10 |
Fibrogen, Inc. |
Treatment method for lung remodeling diseases
|
EP2453017A1
(en)
|
2010-11-12 |
2012-05-16 |
Antisense Pharma GmbH |
Oligonucleotides for use in prophylaxis and/or treatment of TGF-beta1 and TGF-beta2, TGF-beta2 and TGF-beta3, TGF-beta1 and TGF-beta3, or TGF-beta1, TGF-beta2, and TGF-beta3 mRNA overexpressing diseases
|
KR102010598B1
(ko)
|
2010-11-23 |
2019-08-13 |
큐알엔에이, 인크. |
Nanog에 대한 자연 안티센스 전사체의 저해에 의한 nanog 관련된 질환의 치료
|
US9173894B2
(en)
|
2011-02-02 |
2015-11-03 |
Excaliard Pharamaceuticals, Inc. |
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
|
WO2012109495A1
(en)
|
2011-02-09 |
2012-08-16 |
Metabolic Solutions Development Company, Llc |
Cellular targets of thiazolidinediones
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
AU2012242642A1
(en)
|
2011-04-13 |
2013-05-02 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
CN103620036B
(zh)
|
2011-06-09 |
2016-12-21 |
库尔纳公司 |
通过抑制共济蛋白(fxn)的天然反义转录物而治疗fxn 相关疾病
|
CN103597074A
(zh)
|
2011-06-16 |
2014-02-19 |
Isis制药公司 |
成纤维细胞生长因子受体4表达的反义调节
|
BR112014006587B1
(pt)
|
2011-09-20 |
2021-07-27 |
Ionis Pharmaceuticals, Inc |
Composto compreendendo oligonucleotídeo que modula a expressão de gcgr, composição, bem como seu uso no tratamento ou prevenção de diabetes
|
US20130085139A1
(en)
|
2011-10-04 |
2013-04-04 |
Royal Holloway And Bedford New College |
Oligomers
|
RU2014119787A
(ru)
|
2011-10-25 |
2015-12-10 |
Айсис Фармасьютикалс, Инк. |
Антисмысловая регуляция экспрессии gccr
|
EP2825648B1
(en)
|
2012-03-15 |
2018-09-05 |
CuRNA, Inc. |
Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
|
EP2943194A1
(en)
|
2012-09-17 |
2015-11-18 |
Chemedest Ltd. |
Treatment of peripheral neuropathy using gfr(alpha)3 type receptor agonists
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
WO2014152497A2
(en)
|
2013-03-15 |
2014-09-25 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for cognitive disorders
|
US20160129089A1
(en)
|
2013-06-13 |
2016-05-12 |
Antisense Therapeutics Ltd |
Combination therapy
|
IL300444A
(en)
|
2013-09-05 |
2023-04-01 |
Sarepta Therapeutics Inc |
Inclusion of exon 2 is induced by antisense in acid alpha-glucosidase
|
EP3047023B1
(en)
|
2013-09-19 |
2019-09-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Compositions and methods for inhibiting jc virus (jcv)
|
RU2744194C2
(ru)
|
2013-12-02 |
2021-03-03 |
Фио Фармасьютикалс Корп |
Иммунотерапия рака
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
ES2694857T3
(es)
|
2014-02-04 |
2018-12-27 |
Genentech, Inc. |
Smoothened mutante y métodos de uso de la misma
|
US11279934B2
(en)
|
2014-04-28 |
2022-03-22 |
Phio Pharmaceuticals Corp. |
Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
|
WO2015171918A2
(en)
|
2014-05-07 |
2015-11-12 |
Louisiana State University And Agricultural And Mechanical College |
Compositions and uses for treatment thereof
|
WO2015200901A1
(en)
|
2014-06-26 |
2015-12-30 |
The Trustees Of Columbia University In The City Of New York |
Inhibition of serotonin expression in gut enteroendocrine cells results in conversion to insulin-positive cells
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
KR102506169B1
(ko)
|
2014-09-05 |
2023-03-08 |
피오 파마슈티칼스 코프. |
Tyr 또는 mmp1을 표적화하는 핵산을 사용한 노화 및 피부 장애의 치료 방법
|
US11191811B2
(en)
|
2014-11-19 |
2021-12-07 |
The Trustees Of Columbia University In The City Of New York |
Osteocalcin as a treatment for frailty associated with aging
|
MA41795A
(fr)
|
2015-03-18 |
2018-01-23 |
Sarepta Therapeutics Inc |
Exclusion d'un exon induite par des composés antisens dans la myostatine
|
EP3851531A1
(en)
|
2015-06-01 |
2021-07-21 |
Sarepta Therapeutics, Inc. |
Antisense-induced exon exclusion in type vii collagen
|
KR20180026739A
(ko)
|
2015-07-06 |
2018-03-13 |
알엑스아이 파마슈티칼스 코포레이션 |
슈퍼옥시드 디스뮤타제 1 (sod1)을 표적화하는 핵산 분자
|
US10808247B2
(en)
|
2015-07-06 |
2020-10-20 |
Phio Pharmaceuticals Corp. |
Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach
|
US10072065B2
(en)
|
2015-08-24 |
2018-09-11 |
Mayo Foundation For Medical Education And Research |
Peptide-mediated delivery of immunoglobulins across the blood-brain barrier
|
US10954300B2
(en)
|
2015-09-28 |
2021-03-23 |
The Trustees Of Columbia University In The City Of New York |
Use of pentoxifylline with immune checkpoint-blockade therapies for the treatment of melanoma
|
MA45819A
(fr)
|
2015-10-09 |
2018-08-15 |
Sarepta Therapeutics Inc |
Compositions et méthodes pour traiter la dystrophie musculaire de duchenne et troubles associés
|
EP3365446A4
(en)
|
2015-10-19 |
2019-06-26 |
Phio Pharmaceuticals Corp. |
SELF ADMINISTRATION-REDUCED SIZE NUCLEIC ACID COMPOUNDS TARGETING LONGS NON-CODING LONGS
|
CA3007424A1
(en)
|
2015-11-05 |
2017-05-11 |
Children's Hospital Los Angeles |
"mobilizing leukemia cells"
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
KR102522059B1
(ko)
|
2016-04-18 |
2023-04-14 |
사렙타 쎄러퓨틱스 인코퍼레이티드 |
안티센스 올리고머, 및 산성 알파-글루코시다제 유전자와 연관된 질환을 치료하기 위한 이의 사용 방법
|
WO2018209288A1
(en)
|
2017-05-12 |
2018-11-15 |
Massachusetts Institute Of Technology |
Argonaute protein-double stranded rna complexes and uses related thereto
|
EP3697910A4
(en)
|
2017-10-18 |
2021-07-14 |
Sarepta Therapeutics, Inc. |
ANTISENSE OLIGOMERIC COMPOUNDS
|
CA3096274A1
(en)
|
2018-04-06 |
2019-10-10 |
Children's Medical Center Corporation |
Compositions and methods for somatic cell reprogramming and modulating imprinting
|
CA3214540A1
(en)
|
2021-04-22 |
2022-10-27 |
Pasi A. Janne |
Compositions and methods for treating cancer
|